JPRN-jRCT2031220455招募中1 期
A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations
Isui Ayako0 个研究点目标入组 15 人开始时间: 2022年11月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Key Inclusion Criteria:
- •- Histologically or cytologically documented, locally advanced or metastatic NSCLC not amenable to curative surgery or radiotherapy
- •- Disease that has progressed after at least one available standard therapy; or for whom standard therapy has proven to be ineffective, intolerable, or considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.
- •- Documented radiologic disease progression during or after the last systemic anti-cancer therapy before the first dose of furmonertinib.
- •- For patients with EGFR mutations sensitive to osimertinib, the patient must have received osimertinib prior to study enrollment in regions where osimertinib is approved, including the United States (US).
- •Stage 1 dose escalation and backfill cohorts and Stage 2 Cohorts 1, 2, 3, and 4
- •- Patients with CNS metastases (including leptomeningeal disease) are eligible, provided they meet the criteria.
- •Stage 1 Dose Escalation and Backfill Cohorts Inclusion Criteria
- •- Documented validated results from local testing of tumor tissue or blood confirming the presence of an activating, including uncommon, EGFR mutation or HER2 exon 20 insertion mutation performed at a CLIA-or equivalently certified laboratory.
- •Stage 2 Cohort 1 Previously Treated, Locally Advanced or Metastatic NSCLC Patients with EGFR exon 20 Insertion Mutations Inclusion Criteria
- •- Documented validated results from local testing of either tumor tissue or blood confirming the presence of EGFR exon 20 insertion mutations, performed at a CLIA- or equivalently certified laboratory
- •- The patient must have experienced disease progression or have intolerance to treatment with platinum-based chemotherapy.
- •Stage 2 Cohort 2 Previously treated, Locally Advanced or Metastatic NSCLC Patients with HER2 exon 20 Insertion Mutations Inclusion Criteria
- •- Documented validated results from local testing of either tumor tissue or blood confirming the presence of HER2 exon 20 insertion mutations, performed at a CLIA- or equivalently certified laboratory.
- •- The patient must have experienced disease progression or have intolerance to treatment with platinum-based chemotherapy
- •- In regions in which fam-trastuzumab deruxtecan-nxki is approved and available for adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 exon 20 mutations, the patient must have received or be considered not appropriate to receive fam-trastuzumab deruxtecan-nxki.
- •Stage 2 Cohort 3 Previously Treated, Locally Advanced or Metastatic NSCLC Patients with EGFR Activating Mutations
- •- Documented validated results from local testing of either tumor tissue or blood confirming the presence of an EGFR activating mutation, performed at a CLIA- or equivalently certified laboratory.
- •- Patients with CNS metastases may be eligible if meeting additional protocol specified criteria.
- •Stage 2 Cohort 4 Untreated or Previously Treated EGFR-TKI-Naive, Locally Advanced or Metastatic NSCLC Patients with EGFR Uncommon Mutations Excluding EGFR Exon 20 Insertions Inclusion Criteria.
- •- Previously untreated in the locally advanced or metastatic setting or have progressed after at least 1 available standard therapy, or for whom standard therapy has proven to be ineffective, intolerable, or considered inappropriate
- •- Documented validated results from local testing of either tumor tissue or blood confirming the presence of an EGFR Uncommon mutation, performed at a C
排除标准
- •Key Exclusion Criteria
- •- Treatment with chemotherapy, targeted therapy, biologic therapy, or an investigational agent as anti-cancer therapy within 3 weeks or 5 elimination half-lives prior to initiation of furmonertinib, whichever is shorter.
- •- Radiation therapy as cancer therapy within 4 weeks prior to initiation of furmonertinib.
- •- Palliative radiation to bone metastases within 2 weeks prior to initiation of furmonertinib.
- •- AEs from prior anticancer therapy that have not resolved to Grade <= 1 except for alopecia or Grade <= 2 peripheral neuropathy.
- •Stage 2 Cohort 4 Untreated or Previously Treated EGFR-TKI-Naive, Locally Advanced or Metastatic NSCLC Patients with Uncommon EGFR Mutations Exclusion Criteria
- •- Prior treatment with any EGFR-TKIs
- •- Progression during neoadjuvant or adjuvant therapy (e.g., chemotherapy, radiotherapy, immunotherapy or investigational agents) or within 12 months of completion of above therapies
研究者
相似试验
尚未招募
不适用
A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 MutationsPatients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with mutations in a gene called epidermal growth factor receptor (EGFR)/Lung Cancer10038666NL-OMON53437ArriVent BioPharma, Inc.5
进行中（未招募）
1 期
Phase 1b dose escalation and dose expansion study in patients with advanced or metastatic non-small cell lung cancer (NSCLC)Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with mutations in a gene called epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2).NSCLC harboring activating EGFR or HER2 kinase domain mutationsCancerISRCTN99682126Syneos Health UK Limited108
尚未招募
1 期
A Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple MyelomaMultiple MyelomaJPRN-jRCT2031230640Fujikawa Ei164
招募中
1 期
A Phase 1b/2 Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple MyelomaMultiple MyelomaCTIS2023-503439-16-00Janssen - Cilag International228
暂停
1 期
[M20-917] Multiple Myeloma: Lemzoparlimab as Monotherapy and in Combination with Anti-Myeloma Regimens in Subjects with Relapsed/Refractory Multiple MyelomaMultiple MyelomaJPRN-jRCT2071220010Okubo Sumiko163